Polarean Scientific Presentations on Hyperpolarized 129Xenon at Upcoming Medical Meetings
30 Julio 2020 - 7:00AM
Business Wire
- Polarean’s investigational drug/device lung
diagnostic to be prominently featured
- Multiple hyperpolarized Xenon MRI
presentations to be highlighted at two major upcoming scientific
conferences
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology
company, with a proprietary drug‑device combination diagnostic for
the magnetic resonance imaging (MRI) market, announces a number of
presentations highlighting the use of hyperpolarized Xenon 129
(“129Xe”) will be made by leading academic researchers at the
upcoming American Thoracic Society (“ATS”) virtual conference and
the International Society for Magnetic Resonance in Medicine
(“ISMRM”) virtual conference. The ATS and ISMRM conferences are
taking place between August 5-10, 2020 and August 8-14, 2020,
respectively.
Over 40 abstracts related to the use of hyperpolarized 129Xe
were accepted for presentation at ATS 2020. The abstracts listed
below are among those that will be presented as posters on
Wednesday, August 5, 2020:
ATS 2020
Abstract Title and Lead Author
Poster
Number
Session
Number
Coleman EM et al. Hyperpolarized 129Xe
Identifies Ventilation Responders to Glycopyrrolate/Formoterol
Furmarate in Chronic Obstructive Lung Disease
523
D28
Bier EA et al. Monitoring Response to
Inhaled Prostacyclin Therapy with 129Xenon MR Imaging and
Spectroscopy in Patients with Pulmonary Hypertension
593
B56
Neidbalski PJ et al. Hyperpolarized 129Xe
MRI of Regional Capillary-Level Cardio-Pulmonary Dynamics Predict
Outcomes in IPF Patients
622
A68
Bier EA et al. Noninvasive Diagnosis of
Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance
Imaging and Spectroscopy
633
B58
Mummy D et al. Hyperpolarized Xe-129 MRI
Measures of Gas Exchange in Non-specific Interstitial Pneumonia
705
D110
Wang Z et al. Spatial Correlation of
129Xenon Gas Exchange MRI with 99mTc Perfusion Scintigraphy
706
D110
Wang Z et al. Using 129Xenon MR Gas
Exchange MRI to Measure the Membrane and Capillary Components of
DLCO and KCO
707
D110
Mummy D et al. Hyperpolarized 129Xe MRI is
sensitive to therapy response in idiopathic pulmonary fibrosis
713
D110
Shim YM et al. Positive Results from Two
Randomized Phase III Trials Assessing Hyperpolarized 129Xenon Gas
MRI as a Measure of Regional Lung Function as Compared to Imaging
with 133Xenon Scintigraphy
1027
B39
Presentations of the following accepted abstracts will be
delivered at ISMRM on the following days:
ISMRM
2020 Abstract Title and Lead Author
Program Number
Session
Name
Date
Bier EA et al. Noninvasive Diagnosis of
Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance
Imaging and Spectroscopy
2283
Hyperpolarized Gas/Lung MRI
August 8-14
Mummy D et al. Hyperpolarized 129Xe MRI
Measures of Gas Exchange in Non-specific Interstitial Pneumonia
2291
Thoracic & Breast MRI
August 8-14
Niedbalski PJ et al. Imaging Regional
Capillary Cardio-Pulmonary Blood Flow Dynamics using Hyperpolarized
129Xe MRI and Keyhole Reconstruction
0432
Thoracic MRI
August 11
Rankine L et al. Quantitative
dose-dependent changes in regional lung function after radiation
therapy detected using xenon-129 gas exchange MRI
0431
Thoracic MRI
August 11
Lu J et al. Bias field correction in
hyperpolarized 129Xe ventilation imaging
0451
Pulmonary Power
August 11
Wang Z et al. A model for interpreting
hyperpolarized 129Xe exchange MRI
0443
Pulmonary Power
August 11
Additionally, Talissa Altes, MD, Professor and Chair of
Radiology at the University of Missouri will be delivering a
presentation on Xenon lung magnetic resonance imaging (MRI) during
the Lung/Thoracic MRI Session W-02 during ISMRM. Session W-02 takes
place on Tuesday, August 11, 2020 from 1:45 to 2:30 p.m. ET.
Richard Hullihen, Chief Executive Officer of Polarean
commented: “We are pleased to see 129Xenon in MRI highlighted
at these key scientific meetings. It is a testament to the growing
interest in exploring hyperpolarized 129Xenon as a way of advancing
the use of MRI in a non-invasive, non-ionizing functional imaging
platform to assist with the early diagnosis of respiratory
diseases. As well as this, it can be used to monitor progression
and therapeutic response in the patient. Many of the projects being
presented at these two leading conferences have made use of
Polarean’s products to conduct research, highlighting the growing
academic acceptance of the Company’s technology. We hope that the
inclusion of so many sessions on 129Xenon will continue to showcase
Polarean’s important work in the field as we continue to progress
discussions with the regulator regarding the clinical use of our
drug-device system.”
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specializes in the use of hyperpolarized Xenon gas (129Xe) as an
imaging agent to visualize ventilation.129Xe gas is currently being
studied for visualization of gas exchange regionally in the
smallest airways of the lungs, the tissue barrier between the lung,
and the bloodstream and in the pulmonary vasculature. Xenon gas
exhibits solubility and signal properties that enable it to be
imaged within other tissues and organs.
The Group also develops high performance MRI radiofrequency (RF)
coils which are a required component for imaging 129Xe in the MRI
system. The development of these coils by the Group facilitates
emerging applications.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005239/en/
Polarean Imaging plc www.polarean.com /
www.polarean-ir.com Richard Hullihen, Chief Executive Officer Via
Walbrook PR Jonathan Allis, Chairman
Walbrook PR Tel: +44 (0)20 7933 8780 or
polarean@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 (0)7980
541 893 / +44 (0)7876 741 001
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024